Unformatted text preview:  Van Oers JMM, Lurkin I, van Exsel AJA, et al. A simple and fast method for the simultaneous detection of nine fibro- blast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11:7743–8.  Van Rhijn BW, van Tilborg AA, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 2002;10:819–24.  Harnden P, Allam A, Joyce AD, et al. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995;27:169–74.  Alsheikh A, Mohamedali Z, Jones E, et al. Comparison of the WHO/ISUP classification and cytokeratin 20 expres- sion in predicting the behavior of low-grade papillary urothelial tumors. Mod Pathol 2001;14:267–72.  Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59:83–8.  Dyrskjøt L, Kruhøffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathologi- cal classification. Cancer Res 2004;64:4040–8.cal classification....
View Full Document
- Spring '11
- ET AL, bladder cancer, van Oers